Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice.

被引：0

作者：

Yaldizli, O. ^{[1
,2
,3
,4
,5
]}

Barro, C. ^{[1
,2
,3
]}

Michalak, Z. ^{[1
,2
,3
]}

Vehoff, J. ^{[6
]}

Lascano, A. M. ^{[7
,8
]}

Disanto, G. ^{[9
]}

Salmen, A. ^{[10
,11
]}

Derfuss, T. ^{[1
,2
,3
]}

Granziera, C. ^{[1
,2
,3
,4
,5
]}

Achtnichts, L. ^{[12
]}

Findling, O. ^{[12
]}

Nedeltchev, K. ^{[12
]}

Kamm, C. P. ^{[13
]}

Pot, C. ^{[14
]}

Schluep, M. ^{[14
]}

Du Pasquier, R. ^{[14
]}

von Wyl, V. ^{[15
]}

Wuerfel, J. ^{[16
]}

Vallejo, V. ^{[17
]}

Chan, A. ^{[10
,11
]}

Zecca, C. ^{[9
]}

Gobbi, C. ^{[9
]}

Lalive, P. H. ^{[7
,8
]}

Mueller, S. ^{[6
]}

Kappos, L. ^{[1
,2
,3
]}

Benkert, P. ^{[18
]}

Kuhle, J. ^{[1
,2
,3
]}

机构：

[1] Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland

[2] Univ Hosp Basel, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland

[3] Univ Hosp Basel, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland

[4] Univ Hosp Basel, Translat Imaging Neurol ThEVk Basel, Dept Med & Biomed Engn, Basel, Switzerland

[5] Univ Basel, Basel, Switzerland

[6] Cantonal Hosp St Gallen, St Gallen, Switzerland

[7] Geneva Univ Hosp, Geneva, Switzerland

[8] Fac Med, Geneva, Switzerland

[9] Osped Civ, Neuroctr Southern Switzerland, Lugano, Switzerland

[10] Bern Univ Hosp, Bern, Switzerland

[11] Univ Bern, Inselspital, Bern, Switzerland

[12] Cantonal Hosp Aarau, Aarau, Switzerland

[13] Cantonal Hosp Lucerne, Luzern, Switzerland

[14] Lausanne Univ Hosp CHUV, Lausanne, Switzerland

[15] Univ Zurich, Inst Epidemiol Biostat & Prevent, Zurich, Switzerland

[16] Med Image Anal Ctr MIAC AG, Basel, Switzerland

[17] Univ Hosp Basel, Basel, Switzerland

[18] Univ Basel, Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

262

引用

页码：97 / 98

页数：2

共 50 条

[1] Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice
Yaldizli, O.
Benkert, P.
Maceski, A.
Barakovic, M.
Todea, R. -A.
Cagol, A.
Schaedelin, S.
Disanto, G.
Oechtering, J.
Orleth, A.
Rey, D.
Sinnecker, T.
Rahmanzadeh, R.
Zadic, S.
Galbusera, R.
Achtnichts, L.
Aeschbacher, S.
Chan, A.
Conen, D.
Derfuss, T.
Findling, O.
Fischer-Barnicol, B.
Hrusovsky, K.
Kropshofer, H.
Lalive, P.
Lieb, J.
Lorscheider, J.
Maggi, P.
Mueller, C.
Mueller, S.
Naegelin, Y.
Mueller, J.
Oksenberg, J.
Pot, C.
Du Pasquier, R.
Radue, E. -W.
Salmen, A.
Vehoff, J.
Waubant, E.
Wellmann, S.
Wiendl, H.
Wuerfel, J.
Zecca, C.
Berger, K.
Gobbi, C.
Kappos, L.
Leppert, D.
Granziera, C.
Kuhle, J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 26 - 27
[2] Serum neurofilament light chain levels in MS: a promising biomarker of clinical and subclinical disease severity.
Disanto, G.
Barro, C.
Giardiello, A.
Gobbi, C.
Zecca, C.
Kuhle, J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 845 - 845
[3] Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, Jens
Kropshofer, Harald
Haering, Dieter A.
Kundu, Uma
Meinert, Rolf
Barro, Christian
Dahlke, Frank
Tomic, Davorka
Leppert, David
Kappos, Ludwig
[J]. NEUROLOGY, 2019, 92 (10) : E1007 - E1015
[4] Serum Neurofilament Light Chain Levels as an Indicator of Treatment Response in CARE-MS I Patients
Kuhle, J.
Poole, E.
Barro, C.
Michalak, Z.
Leppert, D.
Godin, J.
Shankara, S.
Samad, T. A.
Jacobs, A.
Chung, L.
Roesch, N.
Kaiser, C.
Mitchell, C.
Sormani, M. P.
Kappos, L.
Havari, E.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 23 - 23
[5] Serum neurofilament light chain levels as multiple sclerosis biomarker
Abd-ElHady, Mohamed E.
Hashish, Ehab
Yassine, Imane
Anani, Maha
Negm, Mohamed
[J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2024, 28 (02) : 28 - 32
[6] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity, Progression and Treatment Response in Patients with Multiple Sclerosis
Fabis-Pedrini, Marzena
Kaskow, Belinda
Trend, Stephanie
Carroll, William
Walters, Sue
Maceski, Aleksandra
Kuhle, Jens
Kermode, Allan
[J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP2 - NP2
[7] Neurofilament light chain levels in MS At the doorstep of clinical application
Dalmau, Josep
[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (05):
[8] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity and Treatment Response in Patients with Progressive and Relapsing Multiple Sclerosis
Pedrini, Marzena
Kaskow, Belinda
Trend, Stephanie
Carroll, William
Walters, Susan
Maceski, Aleksandra
Kuhle, Jens
Kermode, Allan
[J]. NEUROLOGY, 2023, 100 (17)
[9] Enhancing the clinical value of serum neurofilament light chain measurement
Kosa, Peter
Masvekar, Ruturaj
Komori, Mika
Phillips, Jonathan
Ramesh, Vighnesh
Varosanec, Mihael
Sandford, Mary
Bielekova, Bibiana
[J]. JCI INSIGHT, 2022, 7 (15)
[10] Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation
Thebault, Simon
Booth, Ronald A.
Rush, Carolina A.
MacLean, Heather
Freedman, Mark S.
[J]. FRONTIERS IN NEUROSCIENCE, 2021, 15

← 1 2 3 4 5 →